Cloud Paweletz
Overview
Explore the profile of Cloud Paweletz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paes T, Buelvas Mebarak J, Magnotto J, Stamatiades G, Kuang Y, Paweletz C, et al.
J Clin Endocrinol Metab
. 2024 Sep;
PMID: 39238355
Context And Objective: The genetic profile of prolactinomas remains poorly understood. Our objective is to identify somatic genetic alterations associated with prolactinomas and to report the identification of an activating...
2.
Saito S, Kono M, Nguyen H, Egloff A, Messier C, Lizotte P, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1934-1944.
PMID: 38372707
Purpose: Neoadjuvant anti-PD1 (aPD1) therapies are being explored in surgically resectable head and neck squamous cell carcinoma (HNSCC). Encouraging responses have been observed, but further insights into the mechanisms underlying...
3.
Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33020238
Background: Blood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB) response are lacking. We hypothesized that changes in systemic cytokine levels with the initial doses of programmed cell death protein...
4.
Ge J, Shu S, Kwon M, Jovanovic B, Murphy K, Gulvady A, et al.
Nat Commun
. 2020 May;
11(1):2350.
PMID: 32393766
BET inhibitors are promising therapeutic agents for the treatment of triple-negative breast cancer (TNBC), but the rapid emergence of resistance necessitates investigation of combination therapies and their effects on tumor...
5.
Stinchcombe T, Janne P, Wang X, Bertino E, Weiss J, Bazhenova L, et al.
JAMA Oncol
. 2019 Aug;
5(10):1448-1455.
PMID: 31393548
Importance: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months....
6.
Fitarelli-Kiehl M, Yu F, Ashtaputre R, Leong K, Ladas I, Supplee J, et al.
Clin Chem
. 2018 Oct;
64(12):1762-1771.
PMID: 30274976
Background: Although interest in droplet-digital PCR technology (ddPCR) for cell-free circulating DNA (cfDNA) analysis is burgeoning, the technology is compromised by subsampling errors and the few clinical targets that can...
7.
Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, et al.
Proc Natl Acad Sci U S A
. 2017 May;
114(22):E4482-E4491.
PMID: 28507152
The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very...
8.
Liu J, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, et al.
Clin Cancer Res
. 2016 Aug;
23(5):1263-1273.
PMID: 27573169
Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with high rates of recurrence and eventual resistance to cytotoxic chemotherapy. Model systems that allow...
9.
Sacher A, Paweletz C, Dahlberg S, Alden R, OConnell A, Feeney N, et al.
JAMA Oncol
. 2016 Apr;
2(8):1014-22.
PMID: 27055085
Importance: Plasma genotyping of cell-free DNA has the potential to allow for rapid noninvasive genotyping while avoiding the inherent shortcomings of tissue genotyping and repeat biopsies. Objective: To prospectively validate...
10.
Karlovich C, Goldman J, Sun J, Mann E, Sequist L, Konopa K, et al.
Clin Cancer Res
. 2016 Jan;
22(10):2386-95.
PMID: 26747242
Purpose: The evaluation of plasma testing for the EGFR resistance mutation T790M in NSCLC patients has not been broadly explored. We investigated the detection of EGFR activating and T790M mutations...